Eris Lifesciences posted a 19 percent net profit rise to ₹99.7 crore in Q3, with revenue up 10 percent to ₹807 crore and plans to acquire the remaining 30 percent in Swiss Parenterals for ₹423 crore.
Eris Lifesciences posted a 19 percent net profit rise to ₹99.7 crore in Q3, with revenue up 10 percent to ₹807 crore and plans to acquire the remaining 30 percent in Swiss Parenterals for ₹423 crore.